---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-005743"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2024-01-23T23:59:59+00:00"
generated_at: "2026-06-06T20:10:43.044326+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Liquidia: United Therapeutics dismisses '793 Patent claims in PH-ILD litigation; '327 Patent remains

## Summary
- On Jan 22, 2024, United Therapeutics stipulated to dismiss all claims related to the '793 Patent in the New Hatch-Waxman Litigation.
- Only claims related to the '327 Patent remain; Liquidia asserts the '327 Patent does not entitle a 30-month regulatory stay.
- The dismissal does not affect the injunction issued in the Original Hatch-Waxman Litigation (filed June 2020).
- Liquidia's motion to set aside the original injunction is fully briefed; awaiting the District Court's decision.

## SEC filing metadata
- accession: 0001104659-24-005743
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2024-01-23T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465924005743/0001104659-24-005743-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465924005743/tm243890d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-005743
- JSON: https://secwatch.observer/filing/0001104659-24-005743.json
- Plain text: https://secwatch.observer/filing/0001104659-24-005743.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.